Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non Operating Income (2016 - 2025)

Lineage Cell Therapeutics' Other Non Operating Income history spans 16 years, with the latest figure at $27000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 103.92% year-over-year to $27000.0; the TTM value through Dec 2025 reached $41000.0, up 106.12%, while the annual FY2025 figure was -$132000.0, 80.3% up from the prior year.
  • Other Non Operating Income reached $27000.0 in Q4 2025 per LCTX's latest filing, down from $219000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $2.3 million in Q4 2023 to a low of -$2.4 million in Q3 2021.
  • Average Other Non Operating Income over 5 years is -$104684.2, with a median of -$231000.0 recorded in 2025.
  • Peak YoY movement for Other Non Operating Income: crashed 798.01% in 2021, then soared 487.44% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at $963000.0 in 2021, then tumbled by 58.67% to $398000.0 in 2022, then skyrocketed by 487.44% to $2.3 million in 2023, then plummeted by 129.47% to -$689000.0 in 2024, then skyrocketed by 103.92% to $27000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Other Non Operating Income are $27000.0 (Q4 2025), $219000.0 (Q3 2025), and $26000.0 (Q2 2025).